Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder

Trial Profile

Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs Rapastinel (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Naurex
  • Most Recent Events

    • 20 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Dec 2014 Results published in a Naurex media release.
    • 17 Nov 2014 According to a Naurex media release, the full results of this trial will be presented at the 53rd Annual Meeting of the American College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top